## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($54.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology**
- Source: Investing News Network | 20251212T020858 | Bullish | Relevance: 100%
- Bio-Techne has announced a strategic collaboration with the Wyss Center for Bio and Neuroengineering (Wyss Geneva) to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens. This partnership aims to overcome the limitations of traditional approaches, accelerate drug discovery, enhance diagnostic development, and advance ethical research practices by reducing reliance on animal models. The initiative will extend Bio-Techne's spatial biology capabilities into 3D multiomic analysis, thereby making these technologies more accessible and fostering innovation in life sciences.

**2. Neuberger Berman Group LLC Has $128.62 Million Stake in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251214T160843 | Somewhat-Bullish | Relevance: 100%
- Neuberger Berman Group LLC reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 17.4% in Q2, now holding 2,499,969 shares valued at approximately $128.62 million. Despite this reduction, institutional ownership remains high at 98.95%, with other firms like Select Equity L.P. and Norges Bank increasing their positions. Analysts maintain a "Moderate Buy" rating for Bio-Techne, with a consensus target price of $71.00, even as Q3 revenues missed estimates and the stock trades at a high P/E ratio.

**3. 4D Advisors LLC Makes New $2.06 Million Investment in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251213T081039 | Somewhat-Bullish | Relevance: 100%
- 4D Advisors LLC has acquired a new stake in Bio-Techne Corp (NASDAQ:TECH) by purchasing 40,000 shares valued at approximately $2.06 million in the second quarter. This move is part of broader institutional investor activity, with several other large investors also modifying their holdings in the biotechnology company. Bio-Techne recently reported slightly lower revenue than expected but met EPS forecasts and announced a quarterly dividend.

**4. Cerity Partners LLC Boosts Stake in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251212T200827 | Somewhat-Bullish | Relevance: 100%
- Cerity Partners LLC increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 20.3% in the second quarter, acquiring an additional 26,898 shares. This brings their total holdings to 159,640 shares, valued at approximately $8.21 million. Other institutional investors also adjusted their positions, with institutional ownership now accounting for 98.95% of the company's stock.

**5. Hereâ€™s Why BioTechne (TECH) Traded Lower in Q3**
- Source: Insider Monkey | 20251211T144304 | Somewhat-Bearish | Relevance: 100%
- Mairs & Power Balanced Fund highlighted Bio-Techne Corporation (NASDAQ:TECH) in its Q3 2025 investor letter, noting the stock's underperformance due to uncertainties in biopharmaceutical funding. Despite the recent weakness, the fund has increased its holdings in Bio-Techne, a company that develops and sells life science reagents and services. The article also notes that Bio-Techne's revenues in Q1 2026 were down 1% year-over-year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 26.7x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.1B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 26.7 |
| Current P/E | 29.6 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.9% to -3.6% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.6pp (needs >3.0% for momentum thesis). Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). RSI neutral at 42. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.62% (CS: 6) | Weak |
| RSI_14 | 41.9 | Neutral |
| MACD Histogram | -0.50 | Bearish |
| vs SMA20 | 0.954x | Below |
| vs SMA50 | 0.955x | Below |
| vs SMA200 | 1.057x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $58.51
- **Stop Loss:** $54.23 (7.3% risk)
- **Target:** $62.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 233
- **Position Value:** $13,632.83
- **Portfolio %:** 13.63%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*